Targeting deadly lung-scarring disease, Peninsula biotech snares $100M crossover round

The new funding has set the table for the South San Francisco biotech to serve up an IPO.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.